{‘She lacks zero qualifications’: this US healthcare community braces for Høeg's tenure at the FDA.

As the United States undertakes historic changes to its vaccination guidelines, an unexpected name has surfaced in a surprising turn: Dr. Tracy Beth Høeg, a Danish American sports medicine doctor and epidemiologist who rose to prominence by expressing skepticism about coronavirus vaccinations during the pandemic and has focused upon possible deaths following COVID-19 immunization in her short position at the Food and Drug Administration.

Scheduled Changes to Pediatric Immunization Schedule

Public health authorities were set to reveal radical revisions to the pediatric vaccination calendar recently, bringing the US with Denmark’s immunization schedule, according to reports – a significant shift that would put the US at odds with much of the world with insufficient data for public health gain. The planned update has been delayed until the new year.

In place of Vinay Prasad, Høeg is set to speak at the event. She was recently named acting director of the FDA’s CDER, the fifth appointee to run the center this year.

Consolidating Power at the Regulatory Body

The acting appointment may indicate a closer partnership between the pharmaceutical and vaccine centers as Dr. Høeg and Dr. Prasad consolidate power at the agency – and it points to a increased emphasis upon reevaluating previously authorized vaccines at the FDA.

Høeg has often pushed for halting certain pediatric vaccine recommendations in the US in order to be more similar to Denmark's approach, a country with universal health coverage and a number of inhabitants roughly the size of Wisconsin’s.

So far comments, she has continued to focus on vaccination policy – typically the responsibility of Prasad, chief of the FDA’s CBER – rather than medication approval.

Doubts Over Expertise

The appointee has no obvious experience in drug development, oversight or management, which has been standard for former leaders of the Center for Biologics Evaluation and Research. She has served at the FDA as a key advisor to the agency head and CBER since March.

“She appears not to have any of the qualifications” for leading the CDER, stated a neurologist and psychiatrist. “She’s never run a clinical trial. She has no expertise in running a major agency. She has no expertise in drug approvals.”

Previous commissioners of CBER would “be deeply familiar with regulatory frameworks and the underlying principles of medication creation”, commented Janet Woodcock. “Objectively, she has not acquired the type of experience that former directors who ran CBER have had.”

This division has an enormous workload at the FDA, the former commissioner stated.

“Everybody just pays attention on the new drug program, but the generic program authorizes a multitude of off-brand pharmaceuticals. There’s a biosimilars division, over-the-counter program and more, and all of those have to be managed,” she noted. “The area you neglect, that is the part that I always told people is going to bite you.”

Additionally, a major management aspect to the position, which manages in excess of 5,000 personnel. “It is a enormous administrative position, if you execute it properly,” Woodcock said.

Agency Reaction and Disputed Policies

In response to inquiries about Dr. Høeg's qualifications and whether this selection indicates increased cooperation among agency officials on immunizations, a press secretary said that the “questions stem from flawed premises”.

“Her experience matches the responsibilities of her job,” the spokesperson explained, pointing to the time Dr. Høeg spent guiding the FDA commissioner on “drug safety and regulatory science, including predictive safety algorithms and vaccine surveillance”.

In her interim role, Dr. Høeg takes over the agency head's controversial expedited review system, a controversial expedited therapy clearance system that allegedly worried her former heads. “By what process are these medications being selected for this voucher program? Who is making the calls?” Dr. Howard questioned. “There’s a lot of secrecy happening at the regulatory body right now.”

Overall, he said, “the FDA seems to be moving towards less stringent regulations of all drugs, aside from immunizations.”

Documented Track Record on Vaccines

Regarding immunizations, Dr. Høeg has a clearer, if problematic, track record, Howard have noted. She authored a analysis using unverified volunteer-provided data to estimate the frequency of heart inflammation after Covid immunization. She consulted for the state of Florida top health official Dr. Joseph Ladapo, who allegedly have altered data to imply Covid vaccines are pose a greater threat than they are.

Included in her “desired changes” for the incoming federal leadership featured revising rules for new vaccines and discontinuing “optional” vaccines, she stated post-election on a podcast. At the FDA, Dr. Høeg has allegedly floated the idea of excluding young men from obtaining Covid vaccines.

“She’s an thorough true believer who commences with her beliefs and tailors the evidence to retrofit the science in a extremely deceptive, untruthful manner,” Dr. Howard argued.

Taking Control and a “Revenge Tour”

Dr. Høeg aligned with other contrarians, {like|